In a field where scientists, investors, regulators, and clinicians rarely share the same table, the Association for Value-Based Cancer Care is convening a curated two-day symposium in New York this October to ask a deceptively simple question: what if the people who shape cancer drug development actually spoke to one another? The Global Cancer Research and Innovation Symposium, set for October 5–6, 2026, is built on the belief that fragmentation is itself a barrier to healing — and that alignment across sectors could accelerate the journey from laboratory discovery to patient care. At its core